Building on the first patient case, Dr. Binod Dhakal and Dr. Prerna Mewawalla discuss how recently presented MajesTEC-9 data may influence treatment selection for patients with relapsed/refractory multiple myeloma (RRMM) who experience an early relapse following frontline therapy.
Using a case-based scenario, Dr. Binod Dhakal and Dr. Carol Ann Huff explore treatment decision-making for a fit patient with relapsed/refractory multiple myeloma (RRMM) experiencing first relapse approximately 30 months after autologous stem cell transplantation.
Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla discuss the growing number of BCMA-directed bispecific antibody options available for patients with relapsed/refractory multiple myeloma (RRMM) and the practical considerations that influence treatment selection.
Dr. Binod Dhakal and Dr. Prerna Mewawalla discuss how evolving dosing strategies are helping improve the real-world use of BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM).
Dr. Binod Dhakal, Dr. Prerna Mewawalla, and Dr. Carol Ann Huff discuss practical strategies for managing the safety profile of BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM).
Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla discuss how differences in patient populations across the MajesTEC clinical program may influence treatment decisions in relapsed/refractory multiple myeloma (RRMM).
Transitioning into a discussion of emerging clinical evidence, Dr. Binod Dhakal and Dr. Prerna Mewawalla examine the efficacy endpoints that are most meaningful when evaluating BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM).
Dr. Binod Dhakal leads a discussion on patient selection for BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM), focusing on how these therapies fit within an increasingly complex treatment landscape.
Dr. Binod Dhakal leads a discussion on the increasingly complex treatment landscape of relapsed/refractory multiple myeloma (RRMM), focusing on how clinicians navigate sequencing decisions among BCMA-directed therapies, including CAR T-cell therapy and bispecific antibodies.
Dr. Binod Dhakal and Dr. Carol Ann Huff discuss how anti-CD38 exposure versus true anti-CD38 refractoriness influences treatment selection in relapsed/refractory multiple myeloma (RRMM).
Learn how clinicians define daratumumab refractoriness vs exposure and why the 60-day rule guides smarter second-line myeloma choices.
Experts unpack earlier use of BCMA bispecific antibodies in relapsed myeloma, guiding second-line choices, sequencing, and real-world safety management.
The premise that early diagnosis of certain types of malignancies improves outcome and survival is a cornerstone of modern medicine. Routine use of the Pap smear has been associated with reduced mortality from cervical cancer. Randomized trials
October 1st 2000
